

1. Record Nr.	UNISA990003122640203316
Autore	PELOSI, Enzo
Titolo	Gli adempimenti ambientali nelle attività di cantiere : rifiuti da costruzione e da demolizione, terre e rocce di scavo, emissioni, rumore, sostanze pericolose, siti inquinati, approvvigionamento e scarichi idrici : [secondo le disposizioni del d. lgs. n. 4 del 16 gennaio 2008] / Enzo Pelosi
Pubbl/distr/stampa	Santarcangelo di Romagna : Maggioli, copyr. 2008
ISBN	978-88-387-4009-7
Descrizione fisica	433 p. ; 24 cm
Collana	Sicurezza & cantiere ; 148
Disciplina	344.450465
Soggetti	Cantieri edili - Sicurezza - Legislazione
Collocazione	XXV.2.K 105 (IG III 1369)
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia

2.	Record Nr.	UNISALENTO991004265233107536
	Autore	Marimón, Luis de
	Titolo	Gran torneo de Kemerí, 1937 / L. de Marimón y B. López Esnaola
	Pubbl/distr/stampa	Madrid : Ricardo Aguilera, 1958
	Descrizione fisica	246 p. ; 16 cm
	Collana	Coleccion Los Grandes Certámenes del Ajedrez ; 3
	Altri autori (Persone)	López Esnaola, Benito
	Soggetti	Scacchi - Tornei
	Lingua di pubblicazione	Spagnolo
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
3.	Record Nr.	UNINA9910139555703321
	Autore	Irving Peter
	Titolo	Clinical Dilemmas in Inflammatory Bowel Disease : New Challenges
	Pubbl/distr/stampa	Hoboken, : Wiley, 2011
	ISBN	1-283-24049-1 9786613240491 1-4443-4257-6 1-4443-4254-1
	Edizione	[2nd ed.]
	Descrizione fisica	1 online resource (286 p.)
	Altri autori (Persone)	SiegelCorey A RamptonDavid ShanahanFergus
	Disciplina	616.344
	Soggetti	Clinical dilemmas Inflammatory bowel diseases Inflammatory Bowel Diseases Inflammatory bowel diseases - Decision making Inflammatory bowel diseases -- Decision making Intestinal Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Disease

Medicine
Health & Biological Sciences
Gastroenterology

Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di contenuto	<p>Clinical Dilemmas in Inflammatory Bowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD- Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD- passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment</p> <p>8 Prebiotics and synbiotics: panacea or placebo</p> <p>9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids</p> <p>17 Steroids in Crohn's disease: do the benefits outweigh the dangers? Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use?</p> <p>26 What is the role of biologics in UC? 27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions</p> <p>34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis? 35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease</p> <p>41 Does anti-TNF therapy increase the risk of complications of surgery?</p>
Sommario/riassunto	The second edition of Clinical Dilemmas in Inflammatory Bowel

Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking
